Safety of axicabtagene ciloleucel for the treatment of relapsed or refractory large B-cell lymphoma

This retrospective study of 37 heavily pre-treated patients with relapsed or refractory diffuse large B-cell lymphoma evaluated incidence and severity of common and severe safety events following axicabtagene ciloleucel treatment in a real-world setting. Almost all patients experienced cytokine release syndrome and/or neurotoxicity. Real-life experience and data are needed to further define and refine management of these unique toxicities.

Source: Clinical Lymphoma, Myeloma and Leukemia - October 8, 2020 Category: Hematology Authors: Allison Grana, Natalia Gut, Kiersten Williams, Joseph Maakaron, Kyle Porter, Basem M. William, Sumithira Vasu, Sam Penza, Jonathan E. Brammer, Ayman Saad, Marcin Puto, Samantha M. Jaglowski, Julianna Roddy Tags: Original Study Source Type: research